Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA).  Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease.  The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…